Typical and atypical pathology in primary progressive aphasia variants

Edoardo G Spinelli, Maria Luisa Mandelli, Zachary A Miller, Miguel A Santos-Santos, Stephen M Wilson, Federica Agosta, Lea T Grinberg, Eric J Huang, John Q Trojanowski, Marita Meyer, Maya L Henry, Giancarlo Comi, Gil Rabinovici, Howard J Rosen, Massimo Filippi, Bruce L Miller, William W Seeley, Maria Luisa Gorno-Tempini, Edoardo G Spinelli, Maria Luisa Mandelli, Zachary A Miller, Miguel A Santos-Santos, Stephen M Wilson, Federica Agosta, Lea T Grinberg, Eric J Huang, John Q Trojanowski, Marita Meyer, Maya L Henry, Giancarlo Comi, Gil Rabinovici, Howard J Rosen, Massimo Filippi, Bruce L Miller, William W Seeley, Maria Luisa Gorno-Tempini

Abstract

Objective: To characterize in vivo signatures of pathological diagnosis in a large cohort of patients with primary progressive aphasia (PPA) variants defined by current diagnostic classification.

Methods: Extensive clinical, cognitive, neuroimaging, and neuropathological data were collected from 69 patients with sporadic PPA, divided into 29 semantic (svPPA), 25 nonfluent (nfvPPA), 11 logopenic (lvPPA), and 4 mixed PPA. Patterns of gray matter (GM) and white matter (WM) atrophy at presentation were assessed and tested as predictors of pathological diagnosis using support vector machine (SVM) algorithms.

Results: A clinical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactive response DNA-binding protein (TDP) inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer disease (AD) pathology in 19% of cases. Each variant was associated with 1 typical pathology; 24 of 29 (83%) svPPA showed FTLD-TDP type C, 22 of 25 (88%) nfvPPA showed FTLD-tau, and all 11 lvPPA had AD. Within FTLD-tau, 4R-tau pathology was commonly associated with nfvPPA, whereas Pick disease was observed in a minority of subjects across all variants except for lvPPA. Compared with pathologically typical cases, svPPA-tau showed significant extrapyramidal signs, greater executive impairment, and severe striatal and frontal GM and WM atrophy. nfvPPA-TDP patients lacked general motor symptoms or significant WM atrophy. Combining GM and WM volumes, SVM analysis showed 92.7% accuracy to distinguish FTLD-tau and FTLD-TDP pathologies across variants.

Interpretation: Each PPA clinical variant is associated with a typical and most frequent cognitive, neuroimaging, and neuropathological profile. Specific clinical and early anatomical features may suggest rare and atypical pathological diagnosis in vivo. Ann Neurol 2017;81:430-443.

Conflict of interest statement

Potential conflicts of interest

Nothing to report.

© 2017 American Neurological Association.

Figures

Figure 1
Figure 1
Flow chart showing inclusion/exclusion process of patients for the present study. Numbers of patients who underwent general cognitive, language and neuroimaging assessments are specified for each group. Abbreviations: AD= Alzheimer’s disease; GGT= globular glial tauopathy; lvPPA= logopenic variant PPA; MND= motor neuron disease; nfvPPA= non-fluent/agrammatic variant PPA; PiD= Pick’s disease; PSP= progressive supranuclear palsy; svPPA= semantic variant PPA; TDP-A, TDP-B, TDP-C= frontotemporal lobar degeneration with TDP-43 depositions type A, type B or type C.
Figure 2
Figure 2
Primary neuropathological diagnosis in primary progressive aphasia (PPA) clinical variants. Values are frequencies (percentages). Abbreviations: AD= Alzheimer’s disease; CBD= corticobasal degeneration; FTLD= frontotemporal lobar degeneration; GGT= globular glial tauopathy; lvPPA= logopenic variant PPA; nfvPPA= non-fluent/agrammatic variant PPA; PiD= Pick’s disease; PSP= progressive supranuclear palsy; svPPA= semantic variant PPA; tau 4R= FTLD-tau with 4 repeats.
Figure 3
Figure 3
Voxel-based morphometry analysis in patients with semantic variant of primary progressive aphasia (svPPA). Patterns of (A) cortical atrophy in all svPPA patients relative to healthy controls; (B) grey and white matter atrophy in each pathological subgroup relative to healthy controls; and (C) grey and white matter atrophy in svPPA patients with frontotemporal lobar degeneration due to tau (FTLD-tau) relative to those with TDP-43 depositions (FTLD-TDP) are shown, overlaid on sections or a three-dimensional rendering of a standard Montreal Neurologic Institute (MNI) brain. Slice labels refer to MNI coordinates. Abbreviations: FTLD= frontotemporal lobar degeneration; GGT= globular glial tauopathy; L= left; PiD= Pick’s disease; R= right; svPPA= semantic variant PPA; TDP-B= frontotemporal lobar degeneration with TDP-43 depositions type B; TDP-C= frontotemporal lobar degeneration with TDP-43 depositions type C.
Figure 4
Figure 4
Voxel-based morphometry analysis showing patterns of grey and white matter atrophy in patients with (A) non-fluent/agrammatic variant of primary progressive aphasia (nfvPPA), (B) logopenic variant of primary progressive aphasia (lvPPA) and (C) mixed PPA patients relative to healthy controls, according to pathological subgroups. All contrasts are overlaid on sections or a three-dimensional rendering of a standard Montreal Neurologic Institute (MNI) brain. Slice labels refer to MNI coordinates. *= a third nfvPPA patient with Pick’s disease showed selective right-sided atrophy (not displayed, see description in body text). Abbreviations: 4R-tau= frontotemporal lobar degeneration with 4-repeat tau depositions; AD= Alzheimer’s disease; FTLD= frontotemporal lobar degeneration; L= left; nfvPPA= non-fluent/agrammatic variant PPA; PiD= Pick’s disease; R= right; TDP-A= frontotemporal lobar degeneration with TDP-43 depositions type A.
Figure 5
Figure 5
Performance of support vector machine classification at a single-patient level is represented for patterns of grey matter (GM, first column), white matter (WM, second column) and a relative combination (GM+WM, third column). Colors and shapes indicate the pathological diagnosis (blue squares, PPA patients with FTLD-tau; green triangles, PPA with FTLD-TDP). Patients with “atypical” pathologies (i.e., svPPA-tau and nfvPPA-TDP) are filled in red. Patients are distributed along a vertical axis according to the probability of belonging to the FTLD-tau group (threshold >0.5) or the FTLD-TDP group (threshold

References

    1. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011 Mar 15;76(11):1006–14.
    1. Chare L, Hodges JR, Leyton CE, et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of neurology, neurosurgery, and psychiatry. 2014 Aug;85(8):865–70.
    1. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Annals of neurology. 2008 Jun;63(6):709–19.
    1. Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimer’s and frontotemporal pathology in primary progressive aphasia. Brain: a journal of neurology. 2014 Apr;137(Pt 4):1176–92.
    1. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nature reviews Neurology. 2010 Feb;6(2):88–97.
    1. Harris JM, Gall C, Thompson JC, et al. Classification and pathology of primary progressive aphasia. Neurology. 2013 Nov 19;81(21):1832–9.
    1. Rohrer JD, Lashley T, Schott JM, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain: a journal of neurology. 2011 Sep;134(Pt 9):2565–81.
    1. Deramecourt V, Lebert F, Debachy B, et al. Prediction of pathology in primary progressive language and speech disorders. Neurology. 2010 Jan 5;74(1):42–9.
    1. Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain: a journal of neurology. 2006 Jun;129(Pt 6):1385–98.
    1. Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Annals of neurology. 2006 Jan;59(1):156–65.
    1. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain: a journal of neurology. 2005 Sep;128(Pt 9):1996–2005.
    1. Josephs KA, Dickson DW, Murray ME, et al. Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer’s disease presenting as logopenic progressive aphasia. Brain and language. 2013 Nov;127(2):127–34.
    1. Rohrer JD, Rossor MN, Warren JD. Alzheimer’s pathology in primary progressive aphasia. Neurobiology of aging. 2012 Apr;33(4):744–52.
    1. Leyton CE, Britton AK, Hodges JR, Halliday GM, Kril JJ. Distinctive pathological mechanisms involved in primary progressive aphasias. Neurobiology of aging. 2016 Feb;38:82–92.
    1. Clark CN, Lashley T, Mahoney CJ, Warren JD, Revesz T, Rohrer JD. Temporal Variant Frontotemporal Dementia is Associated with Globular Glial Tauopathy. Cognitive and behavioral neurology: official journal of the Society for Behavioral and Cognitive Neurology. 2015 Jun;28(2):92–7.
    1. Rohrer JD, Geser F, Zhou J, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2010 Dec 14;75(24):2204–11.
    1. Hodges JR, Mitchell J, Dawson K, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain: a journal of neurology. 2010 Jan;133(Pt 1):300–6.
    1. Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Annals of neurology. 2008 Oct;64(4):388–401.
    1. Leyton CE, Villemagne VL, Savage S, et al. Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using beta-amyloid imaging. Brain: a journal of neurology. 2011 Oct;134(Pt 10):3030–43.
    1. Teichmann M, Kas A, Boutet C, et al. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain: a journal of neurology. 2013 Nov;136(Pt 11):3474–88.
    1. Kloppel S, Peter J, Ludl A, et al. Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. Journal of Alzheimer’s disease: JAD. 2015;47(4):939–54.
    1. Cherubini A, Morelli M, Nistico R, et al. Magnetic resonance support vector machine discriminates between Parkinson disease and progressive supranuclear palsy. Movement disorders: official journal of the Movement Disorder Society. 2014 Feb;29(2):266–9.
    1. Wilson SM, Ogar JM, Laluz V, et al. Automated MRI-based classification of primary progressive aphasia variants. NeuroImage. 2009 Oct 1;47(4):1558–67.
    1. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Annals of neurology. 2004 Mar;55(3):335–46.
    1. Moreno F, Rabinovici GD, Karydas A, et al. A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. Acta neuropathologica communications. 2015;3:19.
    1. Li Y, Chen JA, Sears RL, et al. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS genetics. 2014 Mar;10(3):e1004211.
    1. Kramer JH, Jurik J, Sha SJ, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cognitive and behavioral neurology: official journal of the Society for Behavioral and Cognitive Neurology. 2003 Dec;16(4):211–8.
    1. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta neuropathologica. 2010 Jan;119(1):1–4.
    1. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiology of aging. 1997 Jul-Aug;18(4 Suppl):S1–2.
    1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996 Nov;47(5):1113–24.
    1. Mandelli ML, Vitali P, Santos M, et al. Two insular regions are differentially involved in behavioral variant FTD and nonfluent/agrammatic variant PPA. Cortex; a journal devoted to the study of the nervous system and behavior. 2015 Nov 14;74:149–57.
    1. Zhang Y, Schuff N, Ching C, et al. Joint assessment of structural, perfusion, and diffusion MRI in Alzheimer’s disease and frontotemporal dementia. International journal of Alzheimer’s disease. 2011;2011:546871.
    1. Ashburner J, Friston KJ. Unified segmentation. NeuroImage. 2005 Jul 1;26(3):839–51.
    1. Ashburner J. A fast diffeomorphic image registration algorithm. NeuroImage. 2007 Oct 15;38(1):95–113.
    1. Chang CC, Lin CJ. LIBSVM: A Library for Support Vector Machines. Acm T Intel Syst Tec. 2011;2(3)
    1. Spinelli EG, Caso F, Agosta F, et al. A multimodal neuroimaging study of a case of crossed nonfluent/agrammatic primary progressive aphasia. Journal of neurology. 2015 Oct;262(10):2336–45.
    1. Caso F, Mandelli ML, Henry M, et al. In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology. Neurology. 2014 Jan 21;82(3):239–47.
    1. Catani M, Mesulam MM, Jakobsen E, et al. A novel frontal pathway underlies verbal fluency in primary progressive aphasia. Brain: a journal of neurology. 2013 Aug;136(Pt 8):2619–28.
    1. Gorno-Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology. 2008 Oct 14;71(16):1227–34.
    1. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011 Dec 6;77(23):2034–42.
    1. Leyton CE, Hodges JR, McLean CA, Kril JJ, Piguet O, Ballard KJ. Is the logopenic-variant of primary progressive aphasia a unitary disorder? Cortex; a journal devoted to the study of the nervous system and behavior. 2015 Jun;67:122–33.
    1. Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain: a journal of neurology. 2005 Nov;128(Pt 11):2612–25.
    1. McMillan CT, Irwin DJ, Avants BB, et al. White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. Journal of neurology, neurosurgery, and psychiatry. 2013 Sep;84(9):949–55.
    1. Agosta F, Galantucci S, Magnani G, et al. MRI signatures of the frontotemporal lobar degeneration continuum. Human brain mapping. 2015 Jul;36(7):2602–14.
    1. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PloS one. 2012;7(2):e31302.
    1. Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proceedings of the National Academy of Sciences of the United States of America. 2013 Jun 4;110(23):9535–40.
    1. Nonaka T, Masuda-Suzukake M, Arai T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell reports. 2013 Jul 11;4(1):124–34.
    1. Brettschneider J, Del Tredici K, Irwin DJ, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) Acta neuropathologica. 2014 Mar;127(3):423–39.
    1. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009 Apr 16;62(1):42–52.
    1. Staekenborg SS, Pijnenburg YA, Lemstra AW, Scheltens P, Vd Flier WM. Dementia and Rapid Mortality: Who is at Risk? Journal of Alzheimer’s disease: JAD. 2016 Apr 19;

Source: PubMed

3
S'abonner